Takesako K, Kuroda H, Inoue T, Haruna F, Yoshikawa Y, Kato I, Uchida K, Hiratani T, Yamaguchi H
Biotechnology Research Laboratories, Takara Shuzo Co., Ltd., Shiga, Japan.
J Antibiot (Tokyo). 1993 Sep;46(9):1414-20. doi: 10.7164/antibiotics.46.1414.
Aureobasidin A (AbA) is a novel cyclic depsipeptide antifungal antibiotic. The antifungal activity of AbA was studied in vitro and in vivo in comparison with clinically effective antifungal agents, amphotericin B and fluconazole. AbA was highly active in vitro against many pathogenic fungi, including Candida albicans, Cryptococcus neoformans, Blastomyces dermatitidis and Histoplasma capsulatum. The activity was superior to amphotericin B in most cases. AbA exhibited fungicidal action toward growing cultures of C. albicans. It was highly tolerated by mice and showed good efficacy in the treatment of murine systemic candidiasis when given orally or subcutaneously. AbA's fungicidal action in mice with candidiasis was more effective than fluconazole and amphotericin B.
金担子素A(AbA)是一种新型环缩肽类抗真菌抗生素。将AbA的抗真菌活性与临床有效的抗真菌药物两性霉素B和氟康唑进行了体外和体内研究比较。AbA在体外对许多致病真菌具有高活性,包括白色念珠菌、新型隐球菌、皮炎芽生菌和荚膜组织胞浆菌。在大多数情况下,其活性优于两性霉素B。AbA对白色念珠菌的生长培养物表现出杀菌作用。小鼠对其耐受性良好,口服或皮下给药时,在治疗小鼠系统性念珠菌病方面显示出良好疗效。AbA对念珠菌病小鼠的杀菌作用比氟康唑和两性霉素B更有效。